|Grant Affiliation:||Shattock: Novel Antigens for Mucosal Protection|
|Strategy:||Protein & peptide vaccines|
|Study Type:||Pre-Clinical Non-NHP|
|Study Start Date:||2009-11-13|
|Study Made Public:||2011-09-30|
Neutralization activity of sera collected from rabbits immunized with two types of recombinant clade C HIV gp140, formulated with two types of novel adjuvant, by the intradermal route.
CAVD 305 is a preclinical rabbit study comparing protein and adjuvant regimens administered by the intradermal route.
Sign in to see full information about this study and to download study data.